Explore/

Battling Cancer

Battling Cancer

3.18k followers19 symbols -0.22% Watchlist by Motif Investing

Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.

19 Symbols

To view complete list, get the Yahoo Finance App

Get the Yahoo Finance app

  • Free real-time data
  • News and price alerts
  • Add and edit holdings
  • Track performance
  • Create multiple watchlists
  • Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC
    Zacks10 hours ago

    Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC

    The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.

  • Array BioPharma (ARRY) Q1 Earnings Preview: What to Watch Ahead of the Release
    Zacks10 hours ago

    Array BioPharma (ARRY) Q1 Earnings Preview: What to Watch Ahead of the Release

    Array BioPharma (ARRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For
    Zacks10 hours ago

    Blueprint Medicines (BPMC) Q3 Earnings Preview: What to Look Out For

    Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • What to Expect from Bristol-Myers Squibb’s Q3 Earnings
    Market Realist13 hours ago

    What to Expect from Bristol-Myers Squibb’s Q3 Earnings

    Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from $5.25 billion in the third quarter of 2017 to $5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.

  • See what the IHS Markit Score report has to say about Array Biopharma Inc.
    Markit13 hours ago

    See what the IHS Markit Score report has to say about Array Biopharma Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers
    Zacks13 hours ago

    The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

    The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers

  • Seattle Genetics Sees Hammer Chart Pattern: Time to Buy?
    Zacks14 hours ago

    Seattle Genetics Sees Hammer Chart Pattern: Time to Buy?

    Seattle Genetics has been struggling lately, but the selling pressure may be coming to an end soon.

  • The Wall Street Journalyesterday

    [$$] Bristol-Myers Faces a Costly Delay

    In lung cancer, one of the drug industry’s most lucrative and competitive markets, delays can be expensive. Bristol-Myers Squibb shareholders found that out on Monday. The stock dived 5% after the company said late Friday that the Food and Drug Administration moved back a deadline to rule on a key new drug application.

  • Why Nektar Therapeutics Crashed 17.2% Today
    Motley Foolyesterday

    Why Nektar Therapeutics Crashed 17.2% Today

    Shares in the company are slipping as short-sellers call into question one of its most important clinical-stage drugs.

  • TheStreet.comyesterday

    Mirati Shares Fall After Cancer Trial Progress Report

    fell Monday, Oct. 22, after the drug developer released a progress report of an early stage clinical trial of its lung cancer drug used in conjunction with a Bristol-Myers Squibb Co. The San Diego-based cancer-drug developer revealed some positive progress Monday on its phase 2 trial of sitravatinib used with Bristol-Myers' Opdivo, also know as nivolumab.

  • MarketPulse: Healthcare Slips as Bristol-Myers Squibb Sinks
    Investing.comyesterday

    MarketPulse: Healthcare Slips as Bristol-Myers Squibb Sinks

    Investing.com - Healthcare fell out of favor Monday, weighed down by a slump in shares of Bristol-Myers Squibb and AmerisourceBergen.

  • TheStreet.comyesterday

    Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

    fell sharply Monday after the U.S. Food & Drug Administration extended the approval date for a combination-drug treatment for lung cancer patients. Bristol-Myers said the marketing application for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019. Bristol-Myers said an OS analysis for the same patient sub-group was also submitted to the FDA.

  • TheStreet.comyesterday

    Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

    The Dow Jones Industrial Average traded lower Monday after closing last week with a gain of 0.4%. The S&P 500 also fell into negative territory. The S&P 500 has closed lower in 10 of the past 12 sessions.

  • Why Mirati Therapeutics Inc. Is Plunging Today
    Motley Foolyesterday

    Why Mirati Therapeutics Inc. Is Plunging Today

    Shares tumbled after the company reported clinical data from an important phase 2 trial. Here's what investors need to know.

  • MarketWatchyesterday

    Mirati Therapeutics stock drops 19.5% after cancer trial results

    Mirati Therapeutics Inc. shares dropped 19.5% in extremely heavy Monday morning trade after the company presented results from a phase 2 trial in which its cancer drug sitravatinib was combined with Bristol-Myers Squibb Co.'s cancer drug Opdivo . The trial enrolled patients with non-small cell lung cancer who had their cancer progress while taking a type of cancer drug called an immune checkpoint inhibitor. As of late August, of 56 patients in the trial who could be evaluated, 9 had a confirmed partial or complete response, the company said. Two additional patients had unconfirmed partial or complete responses -- which are awaiting confirmation -- and five others had unconfirmed responses "that will not be confirmed," Mirati said. The company said that in total, 16 patients had partial or complete responses, including the latter two categories of patients in its count. The company also said that 18 patients had tumor reductions of more than 30%, and an early estimate of median duration response was more than nine months. Mirati plans a phase 3 randomized clinical trial comparing a combination of the two cancer drugs with the chemotherapy docetaxel. Bristol-Myers' Opdivo is a checkpoint inhibitor that has already been approved in non-small cell lung cancer. As part of a major trend over the last several years, drugmakers have been testing immuno-oncology drugs like sitravatinib in combination with other cancer drugs, hoping that they might be more effective together. Mirati shares have dropped 41.5% over the last three months to $32.21, compared with a 1.6% slump in the S&P 500 and a 1.1% rise in the Dow Jones Industrial Average .

  • MarketWatchyesterday

    Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug

    Bristol-Myers Squibb Co. shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information from a cancer clinical trial, the U.S. Food and Drug Administration is extending the review period for the company's new drug application by three months. This "major amendment to filing overshadows data presentations at [European Society for Medical Oncology]," a recent and major cancer conference, SunTrust Robinson Humphrey analyst John Boris, who rates the company "buy" with a $67 price target, said. The FDA now aims for an approval decision on the drug by or on May 20, 2019. The trial, called CheckMate-227, is an ongoing phase 3 study testing Bristol-Myers' drug Opdivo plus a low dose of another Bristol-Myers drug, Yervoy, against chemotherapy in metastatic first-line non-small cell lung cancer. The new information that Bristol-Myers submitted to the FDA pertains to overall survival for patients whose tumors have a relatively low level of mutations, or a "tumor mutational burden" (TMB) of less than 10 mutations/megabase. TMB is thought to have promise in cancer treatment, as a way of matching patients with the best therapies for their disease, but the way Bristol-Myers has approached the topic has been controversial, because the drugmaker made changes to its clinical trial to measure TMB while the research was already ongoing. Rival Merck & Co. , meanwhile, is seen as leading the space. The FDA considered the new TMB analysis a "major amendment" to the company's drug application, which is why the review period was extended. Bristol-Myers shares have dropped 9.7% over the last three months, compared with a 1.6% decline in the S&P 500 and a 1.1% rise in the Dow Jones Industrial Average .

  • Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
    Zacksyesterday

    Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?

    Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.

  • Simply Wall St.2 days ago

    Are Bristol-Myers Squibb Company’s (NYSE:BMY) Interest Costs Too High?

    Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Bristol-Myers Squibb Company (NYSE:BMY) a safer option. Risk-averse investors who are attracted to diversified streams Read More...

  • As opioid crisis raged, Insys pushed higher doses of addictive drug and pushed salespeople to ‘own’ doctors
    MarketWatch2 days ago

    As opioid crisis raged, Insys pushed higher doses of addictive drug and pushed salespeople to ‘own’ doctors

    ‘It is much easier to take an existing patient and double their units,’ one sales manager wrote, referring to patients as ‘low hanging fruit.’

  • See what the IHS Markit Score report has to say about Seattle Genetics Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGEN

  • See what the IHS Markit Score report has to say about Blueprint Medicines Corp.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Blueprint Medicines Corp.

    Short interest is low for BPMC with fewer than 5% of shares on loan. The net inflows of $1.69 billion over the last one-month into ETFs that hold BPMC are not among the highest of the last year and have been slowing.

  • Benzinga4 days ago

    Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials

    Merrimack, which focuses on therapies for biomarker-defined cancer, said it has terminated a study dubbed SHERLOC, which evaluated its MM-121 in combination with docetaxel in patients with heregulin-positive non-small cell lung cancer, or NSCLC. Docetaxel is a chemotherapy medication used to treat several cancers, including breast cancer, head and neck cancer, prostate cancer and NSCLC.

  • BMY vs. LLY: Which Stock Should Value Investors Buy Now?
    Zacks4 days ago

    BMY vs. LLY: Which Stock Should Value Investors Buy Now?

    BMY vs. LLY: Which Stock Is the Better Value Option?

  • Will Bristol-Myers move higher? Is Activision Blizzard ov...
    CNBC Videosyesterday

    Will Bristol-Myers move higher? Is Activision Blizzard ov...

    The "Halftime Report" traders answer viewer questions on Bristol-Myers, Activision Blizzard, and JetBlue.